Topics in this section

Hepatitis and HIV: latest news

Hepatitis and HIV resources

  • Liver function tests

    You'll have a number of routine tests to monitor your health as part of your HIV care. If you're taking HIV treatment, you'll also have regular...

    From: Factsheets

    Information level Level 2
  • Managing advanced liver disease

    Over years or decades, chronic hepatitis B or C can cause serious liver disease including advanced fibrosis, cirrhosis or liver cancer (hepatocellular cancer). As scar tissue or tumours...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • HIV & hepatitis

    This booklet gives information for people with HIV who also have hepatitis A, hepatitis B or hepatitis C....

    From: Booklets

    Information level Level 2
  • HIV and hepatitis co-infection

    Hepatitis is a viral infection that affects your liver. Some types – hepatitis B and C – can cause long-term, serious health problems. Many people with HIV...

    From: Booklets

    Information level Level 2
  • Non-HIV-related illnesses – hepatitis

    ‘Hepatitis’ means inflammation of the liver. The liver is the largest internal organ in your body. It is located at the upper right-hand side of the abdomen....

    From: Living with HIV

    Information level Level 2
  • Hepatitis C

    Hepatitis C virus (HCV) is chiefly transmitted by blood-to-blood contact. When the blood of a person with hepatitis C enters the bloodstream of another person,...

    From: Factsheets

    Information level Level 2
  • Hepatitis B

    Hepatitis B is a virus that can cause serious damage to the liver. Hepatitis B is usually transmitted through contact with blood, semen, vaginal fluids,...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1
  • How hepatitis C is passed on

    When the blood of a person who has hepatitis C enters the bloodstream of another person, that person could get hepatitis C.Tiny and unseen traces...

    From: The basics

    Information level Level 1
  • How hepatitis C is passed on during sex

    Hepatitis C can be passed on during sex that could lead to contact with small traces of blood.Many gay men with HIV have picked up...

    From: The basics

    Information level Level 1
  • Other tests

    Blood pressure is the force that the beating heart causes in the arteries, veins, and blood vessels that carry blood around the body. Blood pressure is measured...

    From: Booklets

    Information level Level 2
  • The liver

    The liver is the largest organ in the human body and is situated in the upper right-hand side of the abdomen (tummy), protected by the...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Information on hepatitis C, including transmission, treatment and interactions with HIV and anti-HIV treatment....

    From: HIV treatments directory

    Information level Level 4
  • Hepatitis C virus treatment

    The current preferred treatment regimen for HCV infection is a combination of peginterferon alfa (given by injection) plus ribavirin (given orally). Interferons are human proteins that...

    From: HIV treatments directory

    Information level Level 4

Hepatitis and HIV features

Hepatitis and HIV in your own words

Hepatitis and HIV news from aidsmap

More news

Hepatitis and HIV news selected from other sources

  • The Lancet: Mass imprisonment of drug users driving global epidemics of HIV, hepatitis, and tuberculosis

    The War on Drugs, mass incarceration of drug users, and the failure to provide proven harm reduction and treatment strategies has led to high levels of HIV, tuberculosis, and hepatitis B and C infection among prisoners--far higher than in the general population. With an estimated 30 million people passing in and out of prisons every year, prisoners will be key to controlling HIV and tuberculosis epidemics worldwide, according to a major six-part Series on HIV and related infections in prisoners, published in The Lancet and being presented at the International AIDS Conference in Durban, South Africa.

    17 July 2016 | EurekAlert
  • Fast Advance in Hepatitis C Care Prompts EMA to Revise Clinical Trial Guideline

    EMA has proposed changes to its guideline on clinical trials of direct acting antiviral hepatitis C drugs. The revisions are intended to ensure the guideline reflects the dramatic changes that have happened in the hepatitis C sector since Gilead introduced its blockbuster Sovaldi (sofosbuvir).

    17 July 2016 | Regulatory Affairs Professionals Society
  • Viral hepatitis 'kills as many as Aids or TB'

    Viral hepatitis is one of the leading causes of death and disability across the globe, killing as many people as Aids or TB, research published in the Lancet suggests.

    07 July 2016 | BBC Health
  • HIV-to-HIV Organ Transplants Moving Forward

    Multicenter study preparing for launch, pilot studies already begun

    04 July 2016 | MedPage Today
  • FDA Approves Gilead's Epclusa Combo Pill for All Hepatitis C Genotypes

    On June 28 the U.S. Food and Drug Administration (FDA) approved Gilead Sciences Epclusa, a new once-daily combination pill containing sofosbuvir and velpatasvir, for the treatment of adults with hepatitis C virus (HCV) genotypes 1 through 6 -- the first approved oral pangenotypic regimen. While it is more effective against more types of HCV, Epclusa will cost less than most earlier interferon-free direct-acting antiviral regimens.

    04 July 2016 | HIVandHepatitis.com
  • A boring killer?

    Only 3% of people who have hep C in England have received treatment. What?! How on earth is that acceptable? The problem is that this infection primarily affects injecting drug users and stigma around drug use is preventing public outrage – outrage that could spur on better health treatment.

    14 June 2016 | Addaction
  • Patients who pay £1,000 for life-saving drugs online that would cost NHS £35,000: More and more are doing it - but doctors warn it's a big risk

    Doctors predict that internet drug buyers' clubs are the shape of things to come. Graham Cooke, a consultant in infectious diseases at Imperial College London, says he is supervising NHS patients who have received hep C treatments via fixhepc.com. 'This is a growing trend, as the prices for cancer drugs and other treatments mean they are increasingly unavailable on the NHS,' he adds.

    01 June 2016 | Daily Mail
  • European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

    Epclusa is Gilead’s Third Sofosbuvir-Based Treatment to Receive a CHMP Positive Opinion for the Treatment of Chronic HCV Infection.

    27 May 2016 | Gilled press relase
  • Could hepatitis C treatments help prevent virus transmission?

    In a study looking specifically at HCV infection rates in HIV-positive gay men, the researchers found the proportion of HIV positive gay men with HCV increased slightly from 2004 to 2011, and that current treatment rates were unlikely to reduce HCV transmission over time.

    19 May 2016 | Eurekalert Inf Dis
  • Outside the biomedical box of hepatitis C research

    Interview with Magdalena Harris, Lecturer at the London School of Hygiene and Tropical Medicine, on how she came to work with viral hepatitis, how the field has been changing, and what new research is called for.

    17 May 2016 | BioMed Central blogs
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close